Vaxart, Inc. (VXRT)
Largest Insider Buys in Sector
VXRT Stock Price History Chart
VXRT Stock Performance
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, …
Insider Activity of Vaxart, Inc.
Over the last 12 months, insiders at Vaxart, Inc. have bought $13,578 and sold $0 worth of Vaxart, Inc. stock.
On average, over the past 5 years, insiders at Vaxart, Inc. have bought $14,939 and sold $108.51M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Watson W. Mark (director) — $13,578.
The last purchase of 20,000 shares for transaction amount of $13,578 was made by Watson W. Mark (director) on 2024‑06‑18.
List of Insider Buy and Sell Transactions, Vaxart, Inc.
| 2024-06-18 | director | 20,000 0.01% | $0.68 | $13,578 | +6.06% | |||
| 2022-12-28 | director | 20,000 0.0152% | $0.76 | $15,140 | -1.30% | |||
| 2022-06-22 | Interim CFO | 5,000 0.0037% | $3.22 | $16,100 | -64.14% | |||
| 2022-01-10 | Sale | director | 1,500 0.0012% | $6.01 | $9,015 | -42.60% | ||
| 2021-11-30 | Sale | SVP, Principal Accntng Officer | 3,602 0.003% | $8.00 | $28,816 | -52.20% | ||
| 2021-09-10 | Sale | SVP, Principal Accntng Officer | 1,801 0.0015% | $9.10 | $16,389 | -45.32% | ||
| 2021-08-10 | Sale | SVP, Chief Scientific Officer | 10,000 0.0089% | $10.20 | $102,000 | -45.30% | ||
| 2021-08-10 | Sale | SVP, Principal Accntng Officer | 1,801 0.0016% | $10.00 | $18,010 | -45.30% | ||
| 2021-07-19 | Sale | SVP, Principal Accntng Officer | 1,800 0.0015% | $8.00 | $14,400 | -29.40% | ||
| 2021-06-11 | Sale | director | 10,000 0.0081% | $8.61 | $86,109 | -24.14% | ||
| 2021-06-11 | Sale | SVP, Principal Accntng Officer | 1,802 0.0014% | $8.00 | $14,416 | -24.14% | ||
| 2021-06-09 | Sale | SVP, Principal Accntng Officer | 47,555 0.0412% | $8.00 | $380,440 | -12.70% | ||
| 2021-05-07 | Sale | director | 100,000 0.0819% | $7.13 | $712,750 | -6.18% | ||
| 2021-05-06 | Sale | director | 100,000 0.078% | $6.54 | $653,890 | -2.45% | ||
| 2021-03-04 | Sale | director | 150,000 0.1327% | $6.04 | $906,450 | +16.22% | ||
| 2020-11-23 | Sale | director | 333,334 0.2702% | $6.32 | $2.11M | +1.05% | ||
| 2020-06-29 | Sale | director | 9.39M 13.9107% | $8.29 | $77.8M | -6.34% | ||
| 2020-06-26 | Sale | director | 18.23M 31.5118% | $10.38 | $189.19M | -12.81% | ||
| 2020-06-03 | Sale | director | 400,000 0.5415% | $2.77 | $1.11M | +150.91% | ||
| 2020-06-02 | Sale | director | 800,000 1.0089% | $2.75 | $2.2M | +135.10% |
Insider Historical Profitability
| Watson W. Mark | director | 78125 0.0343% | $0.61 | 2 | 0 | <0.0001% |
| Third Point LLC | other | 6890000 3.0288% | $0.61 | 4 | 1 | <0.0001% |
| Finney Michael J. | director | 452572 0.199% | $0.61 | 3 | 0 | <0.0001% |
| FAHIM RAAFAT E F | President, CEO and CFO | 373474 0.1642% | $0.61 | 3 | 3 | +50% |
| ARMISTICE CAPITAL, LLC | director | 145523 0.064% | $0.61 | 9 | 24 | +502.07% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $20M | 8.7 | 15.38M | New | +$20M | 0.02 | |
| The Vanguard Group | $10.98M | 4.78 | 8.45M | +19.93% | +$1.83M | <0.0001 | |
| Geode Capital Management | $2.85M | 1.24 | 2.19M | +11.87% | +$302,820.11 | <0.0001 | |
| Millennium Management LLC | $2.46M | 1.07 | 1.89M | +956.23% | +$2.22M | <0.01 | |
| BlackRock | $2.31M | 1 | 1.77M | -0.84% | -$19,653.40 | <0.0001 |